secwatch.observer — SEC 8-K summary
======================================

Issuer:     2seventy bio, Inc. (—)
CIK:        0001860782
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001140361-25-018514
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Squibb completes acquisition of 2seventy bio for $5.00/share, total ~$264.6M
--------------------------------------------------------------------------------

- Tender offer expired May 12, 2025; 81.8% of shares tendered (43,542,774 shares).
- Merger completed May 13, 2025 without stockholder vote under DGCL Section 251(h).
- All outstanding shares converted to $5.00 cash; total consideration ~$264.6M.
- 2seventy bio stock delisted from Nasdaq; plans to file Form 15 to suspend SEC reporting.
- Board replaced with Bristol-Myers appointees; former directors resigned, stock plans terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/0001140361-25-018514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/ny20048433x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-018514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer